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 Abstract 18 
STC-1 is a heterogeneous plurihormonal cell line producing several prominent gut peptide hormones. 19 
pGIP/Neo is a genetically selected sub-clone of STC-1 with augmented levels of glucose-dependent 20 
insulinotropic peptide (GIP).  Morphometric parameters, hormone concentrations, mRNA transcripts, 21 
hormone immunocytochemistry and nutrient utilisation/production of these two cell lines were 22 
compared. Proglucagon-derived peptides (Glucagon-like peptide-1 (GLP-1) and - 2(GLP-2)) were lower 23 
in sub-clone cells than progenitor cells. High Content Analysis found altered intracellular GLP-1, GIP, 24 
cholecystokinin (CCK) and peptide YY (PYY) levels and differing hormone co-localisation. The 25 
proportion pGIP/Neo cells containing GIP immunoreactivity (82%) was greater than STC-1 (65%), as 26 
were the proportion with ‘GIP only’, ‘GLP-1 + GIP’ or ‘GIP + PYY’ immunoreactivity. Most surprisingly 27 
mRNA transcripts of the proglucagon and GIP genes were inversely correlated to the levels of their 28 
translated peptides. This strongly suggests that proglucagon and GIP are encoded on ‘translationally 29 
regulated genes’ ‒ a characteristic possessed by other endocrine hormones. Metabolomic profiling 30 
revealed differences in cellular nutrient utilisation/production and that under normal culture 31 
conditions both cell lines exhibit signs of overflow metabolism. These studies provide an insight into 32 
the metabolism and properties of these valuable cells, suggesting for the first time that incretin 33 
hormone genes are translationally regulated.  34 
 35 
 36 
 37 
 38 
 39 
 40 
 41 
 42 
  
1. Introduction  43 
Enteroendocrine cells are the most abundant endocrine cell in the human body (Ahlman & Nilsson, 44 
2001). They are specialised gastrointestinal cells secreting hormones into either, the circulation (for 45 
systemic actions), the extracellular space (for paracrine signalling), or to the enteric nervous system 46 
(for stimulation of nerve endings). There are the ‘L’ cells, originally classified on basis of 47 
enteroglucagon immunoreactivity. These are commonly distinguished from the ‘K’ cells which produce 48 
the incretin hormone, glucose-dependent insulinotropic peptide (GIP), and the ‘I’ cells which produce 49 
cholecystokinin (CCK). The term enteroglucagon encompasses the intestinal proglucagon-derived 50 
peptides: glucagon-like peptide (GLP)-1 (the other incretin hormone), the gut growth factor GLP-2, 51 
and the anorexigenic hormone oxyntomodulin (Baggio & Drucker, 2007). The ‘K’ cells tend to 52 
predominate in the duodenum and decrease in number toward the distal end of the small intestine. 53 
‘L’ cells predominate in the ileum and colon and decrease in number toward the proximal end of the 54 
small intestine (Mortensen, Petersen, & Ørskov, 2000). However, this simplistic view is complicated 55 
by the fact that many enteroendocrine cells simultaneously express more than one hormone. For 56 
example, GLP-1 occurs in subsets of duodenal ‘K’ cells and also immunoreactive GIP occurs in 57 
subpopulations of proximal ‘L’ cells (Mortensen, Petersen, & Ørskov, 2000; Theodorakis et al. 2006). 58 
Ileal and colonic ‘L’ cells are well known to also express PYY or CCK (Roth, Kim & Gordon, 1992).  The 59 
cellular colocalisation of hormones is supported by studies examining and manipulating hormone 60 
profiles in vivo. For example, the targeted ablation of proglucagon-expressing cells with diphtheria-61 
toxin also leads to substantial losses in the number of PYY-, GIP- and CCK-positive cells (Egerod et al. 62 
2012). Similar targeting of GIP-expressing cells reduces pro-CCK but not proglucagon mRNA transcripts 63 
in the duodenum, with a trend toward lower CCK levels in the remaining intestine (Althage et al. 2008). 64 
Duodenal jejunum by-pass surgery in rats (which increases the levels of undigested nutrients arriving 65 
in the distal gut) increases the population of cells co-expressing GIP and GLP-1 in the jejunum (Speck, 66 
et al. 2011). Enteroendocrine cells therefore appear to be flexible, and it has been suggested that the 67 
‘L’, ‘K’ and ‘I’ cells of the small intestine consist of a single cell type which exhibits a hormonal spectrum 68 
which is affected by its location within the gastrointestinal tract but also its exposure to dietary 69 
nutrients (Habib et al. 2012).  70 
Within type 2 diabetes mellitus (T2DM) research there is considerable interest in GLP-1, GIP, CCK, PYY 71 
and other enteroendocrine hormones. GLP-1 receptor agonists and inhibitors preventing GLP-1 72 
degradation, for instance, are currently used in the clinic to treat patients with T2DM (Green & Flatt, 73 
2007). There is a demand for robust enteroendocrine cell models for the routine screening of nutrients 74 
and secretagogues (McCarthy et al. 2015).  Established cell lines used for this purpose include: GLUtag 75 
  
- derived from an intestinal endocrine tumour arising in the large bowel in proglucagon-simian virus 76 
40 large T antigen transgenic mice (Brubaker et al., 1998); NCI-H716 - a human cell line derived from 77 
a poorly differentiated adenocarcinoma of the caecum (De Bruine et al., 1992), and STC-1 which is a 78 
neuroendocrine cell line derived from tumours arising in transgenic mice (McCarthy et al. 2015).  79 
Several years ago there was an interest in genetically engineering enteroendocrine cells to produce 80 
preproinsulin (Cheung et al., 2000; Ramshur, Rull & Wice., 2002) as a novel therapy for type 1 diabetes. 81 
This attempted to exploit similarities between enteroendocrine ‘K’ cells and pancreatic β-cells i.e. 82 
mechanisms regulating hormone production/secretion, the timing of hormone release, and the 83 
presence of prohormone convertases (2 and 3) for posttranslational processing (Ramshur, Rull & Wice, 84 
2002). The initial step before insertion of the insulin gene, involved initially selecting those cells with 85 
a ‘K’ cell phenotype i.e. those with an active GIP promoter.   Ramshur, Rull & Wice (2002) sub-cloned 86 
the STC-1 cell line to produce the pGIP/Neo cell line.  This involved transfection with a plasmid 87 
(pGIP/Neo) encoding neomycin phosphotransferase driven by the GIP promoter, with only those cells 88 
with an active GIP promoter surviving genetic selection (Ramshur, Rull & Wice, 2002). pGIP/Neo cells 89 
therefore provide a unique opportunity to probe STC-1 which natively is a heterogeneous and 90 
plurihormonal population of cells (Brubaker et al., 2003).   Quantitative studies employing a specific 91 
GIP ELISA demonstrate that pGIP/Neo cells produce and secrete 3 to 6 times more GIP whilst retaining 92 
an ability to synthesize and secrete CCK and PYY (Hand et al. 2012). However, further characterisation 93 
studies are needed to assess this potential model for GIP secretion. It has not yet been established if 94 
pGIP/Neo produces proglucagon-derived peptides or retains GLP-1 secretory activity. This study 95 
undertook the first detailed comparison of STC-1 and pGIP/Neo cells. Detailed characterisation studies 96 
involved not only assessing differences in the abundance/secretion of proglucagon peptides (GLP-1 97 
and GLP-2), but also the application of high content analysis (HCA) to examine on a cell-by-cell basis 98 
how intracellular GLP-1, GIP, CCK and PYY (and their co-localisation) are affected.  HCA was also 99 
employed to examine morphometric differences (nuclei size/shape/staining intensity) between 100 
progenitor STC-1 cells and pGIP/Neo cells. Quantitative measures of gene expression (transcript 101 
numbers) for each hormone, as well as, Prohormone convertase 3 (PC3) and Ubiquitin-conjugating 102 
enzyme E2D2 were undertaken. Finally, biochemical profiling of cell-cultured media assessed the 103 
similarities and differences in their nutrient utilisation/production. The findings bring forward new 104 
information relating to the metabolism of enteroendocrine cells and the regulation of incretin 105 
hormone biosynthesis. 106 
2. Materials and Methods 107 
2. 1. Materials 108 
  
Antibodies anti-Gastric Inhibitory Polypeptide (GIP) (Alexa Fluor 647), anti-Cholecystokinin (CCK) 109 
(Alexa Fluor 555) and anti-Peptide YY antibody (Cy3) were purchased from antibodies-online GmbH 110 
(Aachen, Germany) and the Glucagon-like Peptide-1 (GLP-1) antibody (FITC) Biorbyt (Cambridge, UK). 111 
PBS tablets, Triton –X 100 ˜10% solution and Formalin were purchased from Sigma (Dorset, UK). 112 
 113 
2.2. Cell culture 114 
STC-1 and pGIP/Neo cell lines were received as a gift from Dr. B. Wise (Washington University of St. 115 
Louis) with permission from Dr. D. Hanahan (Swiss Institute for Experimental Cancer Research, 116 
Lausanne, Switzerland). STC-1 cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) 117 
containing high glucose, 4.5 g/L, with L-glutamine, and without sodium pyruvate (Gibco, Paisley, UK). 118 
The medium was supplemented with 17.5% foetal bovine serum (FBS), 100 U/mL penicillin and 100 119 
mg/L streptomycin. pGIP/Neo STC-1 cells were also cultured in DMEM containing high glucose, 4.5 120 
g/L, with L-glutamine, and without sodium pyruvate, however the medium contained 10% FBS and 121 
geneticin (G418, 400 ug/mL, Sigma, Poole, Dorset, UK). Both cell medium were incubated in a 5% CO2 122 
humidified atmosphere at 37°C. Cells underwent passage upon reaching 80-90% confluence and were 123 
used between passage numbers 15-50.  124 
2.3 Media accumulation and intracellular content of GLP-1 and GLP-2 125 
STC-1 and pGIP/Neo cell lines were seeded in 24-well plates at a density of 2 x 105/well and incubated 126 
in a 5% CO2 humidified atmosphere at 37oC overnight.  Media was removed and 1 ml of fresh media 127 
added to each well and cells were incubated as above for 72h upon which the media was collected, 128 
centrifuged to remove cellular debris and stored at -80oC prior to ELISA analysis.  129 
To assess the cellular hormone content acid/Ethanol (1.5% v/v HCl, 75% v/v ethanol, 23.5% v/v H2O) 130 
was added and incubated overnight at 4oC.  The incubation solution was removed and centrifuged 131 
(900g, 5 min) to remove cellular debris.  The supernatant was collected and the ethanol evaporated 132 
off using a Speedvac sample concentrator (Genevac, Ipswich, UK).  Samples were reconstituted in PBST 133 
0.1% BSA and stored at -80oC prior to ELISA measurement.  134 
2.4 Determination of GLP-1 and GLP-2 using ELISA 135 
GLP-1 and GLP-2 (Total) concentrations were measured using ELISA kits purchased from Merck 136 
Millipore (Hertfordshire, UK).  The assays were performed in accordance with the manufacturer’s 137 
instructions. The plates were read at 450 nm and 590 nm in a plate reader (Tecan, Safire2).   138 
2.5.0. Immunofluorescence of GLP-1, GIP, CCK and PYY 139 
  
Antibodies were prepared in 1% BSA in phosphate buffered saline with tween (PBST) immediately 140 
prior to adding to cells and protected from the light after preparation. Cells were seeded into 96-well 141 
plates (5 x 104 per well) and cultured overnight at 37 °C in a humidified atmosphere of 5% CO2.  Media 142 
was removed and cells fixed with 10% formalin for 10 min at room temperature.  Cells were washed 143 
(x4) with PBS and permeabilisation solution added and incubated for 30 min at room temperature.  144 
Again, cells were washed (x4) with PBS before blocking solution (0.3 M glycine + 10% goat serum in 145 
1% BSA in PBST (PBS + 0.01% Tween 20) was added for a further 1h.  The blocking solution was 146 
removed and the GLP-1, GIP, CCK or PYY antibody was added (1:200 dilution) and allowed to incubate 147 
overnight. Supernatant was removed and cells were washed with PBS (3 times x 5 min) in the dark, 148 
after which Hoechst staining solution (Thermo Scientific, Hampstead, UK) was added for 10 min. Cells 149 
were washed with PBS (x1) and PBS added to each well and the plate was sealed prior to reading using 150 
the ArrayScan HCS Reader (Thermo, Loughborough, UK). The plate was evaluated at absorbance 350-151 
461 nm and 485-520 nm for Hoechst dye and antibody fluorescence, respectively. Typical micrographs 152 
obtained from the ArrayScan system can be found in Figure 1.  153 
 154 
2.5.1 HCA software parameters  155 
We determined the percentage of cells with immunoreactivity to GLP-1, GIP, PYY or CCK by application 156 
of the HCS Studio Cell Analysis Software (Thermo Scientific, Hampstead, UK). Parameters from the 157 
results database each individual cell were queried by applying the appropriate conditions e.g. GLP-1 158 
only, AND NOT GIP, NOT CCK and NOT PYY (to find cells immunoreactive to GLP-1 ONLY).  159 
This was carried out in a similar manner for each hormone and combination of hormones.  The 160 
percentage of immunoreactive cells was then calculated for each well.  For the in-depth analysis of 161 
GIP immunoreactive cells, reference values were set and values that fell above the lowest quartile but 162 
below the highest quartile were determined to be ‘with-in range’.  Values with immunoreactivity in 163 
the highest quartile were classified as ‘High immunoreactivity’, whereas immunoreactivity values in 164 
the lowest quartile were classified as ‘low immunoreactivity’.  Cells classified as ‘low 165 
immunoreactivity’ were analysed manually to determine the percentage of these cells with ‘zero 166 
immunoreactivity’.    167 
2.6 Gene expression  168 
Cells were seeded at a density of 1 x 106 per well for each cell line and incubated at 5% CO2 humidified 169 
atmosphere at 37oC overnight.   RNA was extracted using the High Pure Isolation Kit Version 12 (Roche 170 
Diagnostics, West Sussex, UK) performed in accordance with the manufacturer’s instructions.  RNA 171 
was quantified on the Nanodrop 8000 and 1 µg was taken forward for cDNA synthesis using the 172 
  
Transcriptor First Strand cDNA Synthesis Kit (Roche Diagnostics, West Sussex, UK).  A total reaction 173 
volume of 20 µL contained 5 µL of cDNA (25 ng), 1 µL of each forward and reverse primer (300 nM), 3 174 
µL of nuclease-free water (NFW) and 10 µL of Mastermix Sybr Green (PrimerDesign, Southampton, 175 
UK).  Primers and conditions for each gene were:  Proglucagon: 5’-GGCACATTCACCAGCGACTAC-‘3 and 176 
5’-CAATGGCGACTTCTTCTGGG-‘3 and conditions were 95oC for 10 min, then 40 cycles of 95oC for 15 s, 177 
60oC for 30 s and 72oC for 30 s. GIP (designed and provided by PrimerDesign Ltd.): 5’-178 
GGACTGGACTCTGACCTTAGC-’3 and 5’-GGCTTTATTGGTTTGGTTCTCTC-‘3 and conditions were 95oC for 179 
10 min, then 50 cycles of 95oC for 15 s and 60oC for 60 s.  PYY: 5’-GGACGCCTACCCTGCCAAACCA-‘3 and 180 
5’-AGTGCCCTCTTCTTAAACCAAACA-‘3 and conditions were 95oC for 10 min, followed by 40 cycles of 181 
95oC for 15 s, 63oC for 30 s and 72oC for 30 s.  CCK: 5’-CTGCGTTTTACGGGAAGTCA-‘3 and 5’-182 
TCAAGTGTAGCAGGGCTTTGG-‘3 and conditions were 95oC for 10 min, followed by 40 cycles of 95oC 183 
for 15 s, 61oC for 30 s and 72oC for 30 s.  PC3: 5’-CGCTGACCTGCACAATGACT-‘3 and 5’-184 
CAGACAACCAGGTGCTGCAT-‘3 and conditions were 95oC for 10 min, followed by 40 cycles of 95oC for 185 
15 s, 61oC for 30 s and 72oC for 30 s.  E2D2: 5’-CATAAAGAGTAGCTGACCGAACCT-‘3 and 5’-186 
GCTGGCCTGGCTTACATTTAG and conditions were 95oC for 10 min, followed by 40 cycles of 95oC for 187 
15 s, 61oC for 30 s and 72oC for 30 s. 18s: 5’-CTTAGAGGGACAAGTGGCG-‘3 and 5’-188 
CGCTGAGCCAGTCAGTGTA-‘3 and conditions were 95°C for 10 min, followed by 45 cycles of 95oC for 189 
10 s, 59oC for 10 s and 72oC for 25 s. The efficiency of each primer was between 95-105% efficiency.  190 
Specificity of the primers was assessed by melt-curve analysis and gel electrophoresis of the PCR 191 
product. Six individual wells from two different cell incubations were run in triplicate for each cell line. 192 
The genes were quantified by the principles of absolute quantification.  A standard curve for each 193 
gene was generated by purifying the relevant PCR product using QIAquick PCR Purification Kit (Qiagen, 194 
Manchester, UK) and quantified on the Nanodrop 8000. The following equations used to determine 195 
the number of molecules present: X g/μL DNA / [plasmid length in base pairs or length of PCR products 196 
x 660]) x 6.022 x 1023 = Y molecules/μL. A standard curve was generated by dilution of the purified PCR 197 
product in nuclease-free water to obtain 2.0 x 108 molecules/µL and 10-fold serial dilutions carried 198 
out to obtain standards ranging from 2.0 x 107 to 2.0 x 100 molecules/µL. Standards were run along 199 
with the samples from each cell line and the number of molecules in each sample was determined. 200 
The 18s gene was also quantified in the same manner and used as a reference gene.  qRT-PCR 201 
experiments were carried out using the Eppendorf MasterCycler Realplex (Rotselaar, Belgium).  202 
 203 
2.7 Metabolomics 204 
Metabolites in the culture medium were determined by a tandem mass spectrometry (MS/MS) 205 
method on a triple-quadrupole mass spectrometer (Xevo TQ-MS, Waters Corporation, USA) using the 206 
  
Absolute IDQ p180 Kit (BIOCRATES Life sciences, Innsbruck, Austria), which could simultaneously 207 
quantify 187 metabolites including amino acids, acylcarnitines, phospho- and sphingolipids, hexose 208 
(glucose), and biogenic amines. Briefly, 10 μL of culture medium was applied to a 96-well plate 209 
containing isotopic internal standards. Amino acids and biogenic amines were derivatized using 210 
phenylisothiocyanate (PITC) before analysis and extracted with 5 mmol/l ammonium acetate in 211 
methanol. Amino acids and biogenic amines were analysed by UPLC-MS in the multiple reaction 212 
monitoring (MRM) mode. The concentrations of metabolites were expressed as µmol/L. 213 
 214 
2.8 Statistical Analysis  215 
Results were expressed as means ±SEM. Data were compared using the unpaired Student’s t-test. 216 
Groups were considered to be significantly different if p˂0.05 (*P≤0.05; **P≤0.01; ***P≤0.001). 217 
3. Results   218 
3.1 Media accumulation and cellular content of GLP-1 and GLP-2 in cell lines 219 
Quantitative measurements of total GLP-1 found that STC-1 progenitor cells accumulated significantly 220 
more GLP-1 in the media than pGIP/Neo cells (72h; 1.7-fold; P≤0.01).  Total cellular GLP-1 content was 221 
also significantly greater in STC-1 cells than pGIP/Neo cells (2.5-fold; P≤0.05) (Figure 2A).  GLP-2, the 222 
other major preproglucagon product exhibited a similar trend. The progenitor STC-1 cell line displayed 223 
greater GLP-2 media accumulation (72h; 2.4-fold; P≤0.001) and greater cellular GLP-2 content (2.5-224 
fold, P≤0.001) than the pGIP/Neo cell line (Figure 2B). 225 
3.2 Morphometric differences between STC-1 and pGIP/Neo cell lines  226 
HCA detected modest but significant morphometric differences between STC-1 and pGIP/Neo cell 227 
lines in terms of nuclei size, nuclei shape, and intensity nuclei (Hoechst) staining. All parameters were 228 
significantly greater in pGIP/Neo cells (Nuclei size: 1.02-fold, P≤0.01, shape: 1.003-fold, P≤0.05; 229 
fluorescence intensity: 1.1-fold, P≤0.001, Figure 3).   230 
3.3 GLP-1, GIP, PYY and CCK immunoreactivity in STC-1 and pGIP/Neo cell lines  231 
GLP-1 immunoreactivity was significantly greater in the STC-1 cell line (1.7-fold; P≤0.001) (Figure 4A) 232 
whereas GIP immunoreactivity was greatest in the pGIP/Neo cell line (1.6-fold; P≤0.001) (Figure 4B). 233 
There appeared to be a trend of increased PYY (1.4-fold) (Figure 4C) and CCK (1.1-fold) (Figure 4D) 234 
levels in the pGIP/Neo cell line but neither of these were significantly different.  235 
3.4 Gene transcripts levels in STC-1 and pGIP/Neo cell lines 236 
  
The levels of gene transcripts for hormones differed between the cell lines. The mRNA copy number 237 
for the proglucagon gene expression (4.1-fold; P≤0.001; Figure 5A) and the PYY gene (5.3-fold; 238 
P≤0.001; Figure 5C) were significantly higher in the pGIP/Neo cell line than the STC-1 cell line. 239 
Contrastingly, the mRNA copy number for the GIP gene (47.2-fold; P≤0.001; Figure 5B) and the CCK 240 
gene (2.7-fold; P≤0.001; Figure 5D) was significantly higher in the STC-1 cell line than the pGIP/Neo 241 
cell line. The levels of gene transcripts for proteins involved in posttranslational processing also 242 
differed between the cell lines.  E2D2 (a ubiquitin-conjugating enzyme) and the Prohormone 243 
Convertase 3 gene (PC3) had higher mRNA copy numbers in the pGIP/neo cell line, increased by 1.8-244 
fold and 1.7-fold (P≤0.01; Figure 5E & 5F), respectively.  245 
3.5 Hormone immunoreactivity profiles of STC-1 and pGIP/Neo cells 246 
The percentage (%) of cells classified as ‘GLP-1 only’, ‘PYY only’ or ‘CCK only’ did not significantly differ 247 
between STC-1 and pGIP/Neo cell lines (Figure 6A & 6C). In contrast, the % of cells classified with ‘GIP 248 
only’ immunoreactivity was significantly higher in the pGIP/Neo cell line (3.5-fold; P≤0.05). Similarly, 249 
the % of cells which co-produced GLP-1+GIP, and GIP+PYY was significantly higher (2.5-fold (P≤0.01) 250 
and 1.3-fold (P≤0.05), respectively; Figure 6A) but not for GIP+CCK (Figure 6C).  There were no 251 
significant differences in the % of STC-1 and pGIP/Neo cells co-producing GLP-1+PYY (Figure 6A), 252 
however with pGIP/Neo cells there were significantly more GLP-1+CCK co-producing cells (1.8-fold; 253 
P≤0.01; Figure 6C).  The % of cells with no immunoreactivity for the hormones tested (‘Undefined’) 254 
did not differ between the cell lines either when they were co-stained for PYY or co-stained for CCK.  255 
3.6 Differences in GIP immunoreactivity between STC-1 and pGIP/Neo cell lines 256 
The increased immunoreactivity of the pGIP/Neo cell line was probed in more detail by examining 257 
overall proportion of cells with low, within range and high GIP immunoreactivity. The % of cells with 258 
‘GIP within range’ immunoreactivity did not significantly differ between the STC-1 and pGIP/Neo cell 259 
lines (Figure 7A). However there were significantly fewer pGIP/Neo cells with ‘Low GIP 260 
immunoreactivity’ (1.6-fold; P≤0.001; Figure 7A), and at the same time there were significantly more 261 
cells of ‘High GIP immunoreactivity’ (2.1-fold, P ≤ 0.01).  Of the cells classified with ‘Low GIP 262 
immunoreactivity’ 56-70% of these contained no GIP immunoreactivity at all, but did not significantly 263 
differ between STC-1 and pGIP/Neo cell lines (Figure 7B). Overall, approximately 65% of STC-1 cells 264 
and 82% of pGIP/Neo had GIP immunoreactivity (P≤0.01).       265 
3.7 LC-MS metabolite profiling of cultured media from STC-1 and pGIP/Neo cells 266 
For both the STC-1 and pGIP/Neo cells the culture media levels of 187 metabolites were measured 267 
before and after 72h of culturing. Of the 187 metabolites only 30 were found at measurable levels in 268 
  
media.  The levels of phenylalanine, threonine, ADMA, creatinine, kynurenine, Met-SO and SDMA did 269 
not differ before and after culture in either cell line.  The metabolite which most dramatically changed 270 
following the period of culture was Pro which increased by 724% (P≤0.001; Supplementary Table 1) in 271 
STC-1 cells and by 2376% (P≤0.01) in pGIP/Neo cells.   Both cell lines utilised glucose in their respective 272 
media to a similar extent (60-66%; P≤0.001). Propionylcarnitine decreased 46% (P≤0.001) in STC-1 cells 273 
and decreased 72% (P≤0.01) in pGIP/Neo cells. The total amount of amino acids or essential amino 274 
acids utilised during the culture period did not significantly differ for either STC-1 cells or pGIP/Neo 275 
cells.  However, significant utilisation of the branched chain amino acids (i.e. leucine, isoleucine and 276 
valine) was evident and a number of individual amino acids were significantly affected. Glutamine and 277 
lysine decreased by 44% and 43% respectively (P≤0.01) in STC-1 cells, and by 24% and 32% respectively 278 
(P≤0.01) in pGIP/Neo cells.  In contrast the levels of serine increased by 14% (P≤0.05) and 19% (P≤0.05) 279 
in STC-1 and pGIP/Neo cells, respectively. Alanine also increased in cultured media from both cell lines 280 
but with STC-1 cells the increase was very modest (10%; P≤0.05) compared with pGIP/Neo cells (116%; 281 
P≤0.001). A number of other differences in cultured STC-1 and pGIP/Neo media were evident. Taurine 282 
increased by 105% after STC-1 culture (P≤0.001) but decreased by 56% after pGIP/Neo culture 283 
(P≤0.05). Arginine and glutamic acid levels were unaffected by STC-1 culture, however, after pGIP/Neo 284 
culture arginine was decreased by 26% (P≤0.001), and glutamic acid was increased by 76% in the 285 
pGIP/Neo media (P≤0.05).  On the other hand ornithine and Alpha-AAA were decreased 58% (P ≤ 286 
0.001) and 29% (P≤0.05) respectively after STC-1 culture but neither were affected by pGIP/Neo 287 
culture.   288 
4. Discussion  289 
pGIP/Neo cells were originally developed by insertion of an expression vector containing nucleotides 290 
-1153 to +7 of the rat GIP promoter linked to the neomycin phosphotransferase gene into STC-1 cells 291 
(Ramshur, Rull & Wice 2002). Preferential selection of cells with an active GIP promoter using geneticin 292 
resulted in the pGIP/Neo sub-clone cell line.   These are the first in-depth characterisation studies of 293 
pGIP/Neo. They provide a detailed overview of the various hormone producing cell-types present 294 
within these heterogeneous GIP-enriched cells (Hand et al. 2012). The data offer insights into the 295 
cellular processes regulating incretin hormone biosynthesis in vitro.   296 
 297 
We have demonstrated that the secretion of GIP’s sister hormone, GLP-1 is substantially 298 
greater in progenitor STC-1 cells than the sub-clone cells. Around 41% less accumulated in pGIP/Neo 299 
cell media over 72h.  This finding was corroborated by quantitative measurement of intracellular GLP-300 
1 content as assessed by ELISA.  This therefore is the first definitive demonstration that pGIP/Neo STC-301 
  
1 cells shift away from a GLP-1-producing cell phenotype.  Using HCA and a GLP-1-specific antibody 302 
we were then able to probe relative levels of enteroendocrine hormones and assess their co-303 
localisations within individual cells.  Once again this confirmed comparatively higher GLP-1-304 
immunoreactivity in progenitor STC-1 cells. Proglucagon gene expression was also assessed in both 305 
cell lines, but expression was much greater in pGIP/Neo STC-1 cells, not the progenitor cells. As these 306 
findings were entirely contrary to the quantitative peptide measurements and HCA data we re-307 
checked this several times even developing a qRT-PCR measuring the number of proglucagon mRNA 308 
transcripts. Following translation the proglucagon is processed to form GLP-1 by prohormone 309 
convertase 3 (PC3 or sometimes referred to as PC1).  We assessed PC3 gene expression and we 310 
quantified another proglucagon-derived peptide GLP-2 to check the discrepancy in proglucagon mRNA 311 
and GLP-1 peptides.  We found that in a manner similar to GLP-1 both GLP-2 media accumulation and 312 
intracellular storage (as assessed quantitatively by ELISA) were significantly greater in the progenitor 313 
STC-1 cell line. However, mRNA copy numbers of PC3 were significantly higher in pGIP/Neo STC-1 cells.  314 
This demonstrates that there is no direct correlation between the number of proglucagon mRNA 315 
copies and the actual abundance of GLP-1 and GLP-2 peptides.  Therefore when studying the biology 316 
of enteroendocrine cells hormone mRNA and peptide measurements should be viewed as 317 
complimentary (Greenbaum et al., 2003). The lack of correlation between the mRNA levels and 318 
peptide abundance in progenitor and sub-clone cells is potentially very informative.  It has been 319 
common practice to consider mRNA abundance as the major determinant of protein abundance, but 320 
the many complicated and varied post-translational steps responsible for converting mRNA into 321 
protein are frequently overlooked. Emerging evidence suggests that transcript abundance only 322 
partially predicts protein abundance.   Vogel & Marcotte (2012) reported that there is only around a 323 
40% correlation between mRNA and protein abundance, which means that approximately 60% of 324 
variations arise from a combination of post-transcriptional regulation and measurement noise. The 325 
strongest contribution evidently comes from protein translation, and it has been proposed that 326 
differences could purely be due to energy constraints within the gene expression system 327 
(Schwanhausser et al., 2011). Protein synthesis actually consumes more than 90% of a cell’s energy 328 
but less than 10% is consumed by transcription, and so much less energy is required to transcribe 329 
mRNA than to translate and process the actual protein. Enteroendocrine cells represent a system 330 
which is required to respond quickly to external stimuli and Schwanhausser et al., (2011) found that 331 
such systems are characterised by stable mRNA copies and unstable proteins, and classified these as 332 
‘translationally regulated genes’.  For example, when two ferritin proteins are rapidly upregulated in 333 
response to iron, this upregulation is not dependant on the generation of more mRNA but on dynamic 334 
translation (Hentze, Muckenthaler & Andrews, 2004).  Similarly, Han et al. (2007) found an increase in 335 
  
insulin secretion in a cloned cell line but no significant change in mRNA expression and they suggested 336 
this was due to vesicular release rather than transcriptional regulation of the GIP promoter.  This adds 337 
weight to the argument that translation of the protein is regulated more stringently than transcription. 338 
There is some speculation that other homeostatic genes regulate themselves in a similar manner and 339 
the proglucagon gene could certainly be categorised as homeostatic.  GLP-1 plays an important role 340 
in glucose homeostasis and responds rapidly to nutrient ingestion therefore it would seem 341 
appropriate that it is regulated at the translational rather than transcriptional level.  So it would appear 342 
that translational regulation is potentially very important for the biosynthesis of these hormones and 343 
it explains the startling discrepancy between the progenitor and sub-clone cell lines examined here. 344 
Another important consideration is the incorporation of polysomes.  A polysome is a complex 345 
containing an mRNA molecule with two or more ribosomes and is indicative of an increase in the rate 346 
of translation (Johannes et al., 1999, Mikulits et al., 2000).  Greenman et al. (2007) investigated 347 
proteins regulated by glucose through changes of their protein synthesis via translational profiling 348 
(rather than transcriptional) using microarray analysis of MIN6 cells acutely incubated at either low or 349 
high glucose concentrations.  A total of 313 transcripts, particularly those associated with metabolism 350 
or gene expression were associated with polysomes.  Furthermore, it appeared possible for transcripts 351 
to be redistributed to heavier polysomes in the presence of a high glucose environment. Interestingly, 352 
glucose-induced proinsulin synthesis is mainly achieved by enhancing the translation efficiency of 353 
proinsulin mRNA pre-existent on the membrane-bound polysome in pancreatic islets (Itoh & 354 
Okamoto, 1980).  Similar studies in enteroendocrine cells regarding incretin hormones have not yet 355 
been carried out but given the similarities between GIP and insulin biosynthesis (Ramshur, Rull & Wice, 356 
2002), it is not unreasonable to suggest a similar mechanism for incretin hormones. In general, it is 357 
seems important to remember that mRNAs and proteins are information carriers of the cell.  Their 358 
degradation or translation can be an in-built timer controlling the persistence of genetic information 359 
(Pedraza & Paulsson, 2008).  Sufficient quantities of peptide produced by the cell can trigger negative 360 
feedback reducing mRNA transcription which is another reason to explain the lack of correlation in 361 
this study.  362 
Indeed, GIP mRNA and protein abundance did not correspond either.  In this case the relationship was 363 
reversed with pGIP/Neo having significantly fewer mRNA GIP transcripts, yet significantly greater 364 
intracellular GIP. Both GLP-1 and GIP are post-translationally processed by PC3. Therefore it appears 365 
that the pGIP/Neo expression vector in the sub-clone cells has preferred translation and processing of 366 
GIP rather than GLP-1. The greater constitutive GIP producing status of the cells results in reduced 367 
mRNA levels of GIP because this is more efficient for the cell. With this in mind, the default position 368 
of progenitor STC-1 cells is to favour GLP-1 production; hence the cells generating more GIP mRNA in 369 
  
order to ensure adequate supply of GIP should the cells be required to switch production.  370 
Furthermore, since the sub-clone cell line has significantly more expression of PC3 gene for both GLP-371 
1 and GIP processing this may suggest that this cell line has an enhanced ability to post-translationally 372 
process peptides than the STC-1 cell line.  In addition, we detected significantly greater gene 373 
expression of the ubiquitin-conjugating enzyme E2D2 (E2D2) in pGIP/Neo compared with the STC-1 374 
cell line. Ubiquitin enzymes determine protein turnover, regulation, molecular function and provide a 375 
complex regulation of the proteome and the E2 enzymes have been ascribed a role in deciding the 376 
‘life or death’ of a protein (van Wijk & Timmers, 2010).  At the present time there is no evidence that 377 
E2D2 influences the fate of any of the peptides discussed here, but we do note a correlation between 378 
PC3 expression, E2D2 expression, and increased GIP production.  The caveat here is that only mRNA 379 
was measured for PC3 and E2D2 and the corresponding protein levels or enzyme activities have not 380 
been assessed.  381 
We observed a trend of higher intracellular PYY and CCK levels in pGIP/Neo compared with STC-1 but 382 
this was not statistically significant.  However, there were significantly more PYY mRNA transcripts in 383 
pGIP/Neo, and in contrast, significantly fewer CCK mRNA transcripts.  It has not been established 384 
precisely how these prepropeptides are processed to their biologically active forms but prohormone 385 
convertases are thought to be involved (Yoon & Beinfeld, 1997).  Once again the differences in 386 
PYY/CCK expression did not reflect differences in PYY and CCK immunoreactivity (HCA), but it is 387 
entirely possible that these peptide hormones are more tightly regulated at a translational level, 388 
rather than at a transcriptional level.   389 
The in-depth cell-by-cell analysis using the HCA also gave an interesting insight into the co-localisations 390 
of four enteroendocrine hormones in both of these cell lines.  Technical constraints meant that we 391 
could not measure all four hormones simultaneously (four-channel fluorescent imaging, but with one-392 
channel reserved for Hoechst nuclear staining). Therefore, hormones were measured in two sets of 393 
triplets (i.e. GLP-1, GIP & PYY and GLP-1, GIP & CCK) with the two incretins serving as reference points. 394 
HCA data clearly verify that the pGIP/Neo STC-1 cell line contains more cells with more GIP-395 
immunoreactivity than the progenitor STC-1 cell line. There were not just increases in cells which were 396 
exclusively GIP-immunoreactive but also an increase in the number of cells which were 397 
immunoreactive for GLP-1 + GIP, and for GIP + PYY. Overall, the number of cells with GIP 398 
immunoreactivity increased by 17% in the pGIP/Neo cell line. GLP-1 and PYY are both associated with 399 
the ‘L’ cell phenotype (Schwartz & Holst, 2010), therefore an increase of either in combination with 400 
GIP seems logical. Cells with immunoreactivity for GLP-1 + CCK were also significantly higher in the 401 
pGIP/Neo cell line.  Roth, Kim & Gordon (1992) has suggested that the enteroendocrine cell lineage 402 
has two branches one of which produces CCK, GLP-1, PYY, and neurotensin.  Increased GLP-1 + CCK 403 
  
immunoreactivity suggests such a lineage exists within pGIP/Neo.  Interestingly, both cell lines are 404 
comprised of 20–30% which are exclusively immunoreactive for PYY or CCK, which is much more than 405 
either GLP-1 or GIP only cells. Initially STC-1 cells were employed as a model of native CCK-producing 406 
‘I’ cells and on occasion it has been used to measure GLP-1 secretory activity. Only recently, PYY was 407 
discovered to be present in the STC-1 cell line (Geraedts et al. 2009; Hand et al. 2012) but here we 408 
report the true extent of PYY abundance. Approximately 56% of STC-1 cells, and 67% of pGIP/Neo STC-409 
1 cells produce detectable PYY. Egerod et al. (2012) reported that although CCK is the most abundantly 410 
expressed peptide hormone at the RNA level in CCK-eGFP-positive mouse intestinal tissue cells in the 411 
duodenum, PYY was expressed to a similar level within these cells. They also found cells co-store these 412 
hormones in the gastrointestinal (GI) tract of mice.  This work demonstrates that enteroendocrine 413 
cells are less heterogeneous than previously thought which is in keeping with the concept of fewer 414 
cell types but exhibiting a hormonal spectrum (Habib et al., 2012; Egerod et al. 2012). Importantly, the 415 
percentage of cells classified here as ‘undefined’ could represent cells possessing immunoreactivity 416 
for three or more of the hormones.  417 
As mentioned the percentage of cells containing some form of GIP immunoreactivity i.e. including low 418 
(minus zero immunoreactivity), within range, or high increased from 65% in the progenitor cell line to 419 
82% in pGIP/Neo. The percentage of cells with zero GIP immunoreactivity tended to be lower in 420 
pGIP/Neo but was not significant. However, the percentage of pGIP/Neo cells with intense GIP 421 
immunoreactivity was significantly increased, and the percentage with low GIP immunoreactivity 422 
significantly decreased.  This proves the utility of HCA in characterising novel cell lines by showing how 423 
the pGIP/Neo population gives rise to more GIP peptide.  424 
One potential limitation of the current study is that the two cell lines have different cell culture 425 
medium requirements. The higher serum levels of STC-1 (17.5% FBS versus 10% FBS for GIP/Neo) could 426 
potentially increase cell growth or cell density, which in turn could increase enteroendocrine 427 
hormones levels. Neither our pilot studies (72h) nor the High Content Analysis studies (<24h) detected 428 
any significant differences in the rate of cell proliferation between the two cell lines. Furthermore, it 429 
should be mentioned that some hormones i.e. GLP-1 and GLP-2 actually decreased rather than 430 
increased. Nonetheless, if future studies could harmonise the cell culture medium used for the two 431 
cell lines this would minimise any confounding effect from this.  432 
 433 
Metabolomic profiling of media (pre-culture versus cell-cultured) culture assessed nutrient utilisation 434 
of the cell lines.  Since the composition of the cell culture media differs between cell lines pairwise 435 
statistical comparisons were not possible.  However, metabolite profiling did reveal a number of 436 
  
similarities and differences in the nutrient utilisation/production of cell lines. At first glance the energy 437 
requirements of the two cell lines appear broadly similar. Reductions in glucose in the media suggest 438 
equivalent levels of glycolytic activity.  Furthermore, another key source of cellular energy, glutamine, 439 
was utilised to similar extent in both cell lines. A major difference between cell lines was that pGIP/Neo 440 
cells had much greater propensity to utilise propionylcarnitine. Propionylcarnitine is a carrier of 441 
propionate which enters the Kreb’s cycle and contributes to cellular energy (Brevetti et al., 1997).  442 
 443 
Both cell lines appeared to produce substantial quantities of proline, which is not surprising given that 444 
other cell lines have been reported to produce and release proline into the cell culture medium 445 
(Genzel et al. 2004).  Proline production apparently results from overflow metabolism of glutamine 446 
which ends in excess production of ammonium and the amino acids alanine, proline, ornithine, 447 
asparagine, glutamate, serine and glycine (Ljunggren and Häggström, 1992).  We observed significant 448 
increases in alanine and serine in both cell lines and in pGIP/Neo cell-cultured media glycine was also 449 
increased. Closer examination of proline, alanine, serine and glycine suggests that both cell lines, but 450 
possibly to a greater extent the pGIP/Neo cell line exhibit signs of overflow metabolism i.e. an 451 
incomplete oxidation of an abundant energy source (despite aerobic conditions) resulting in an 452 
excretion of organic, often inhibitory end products (Amribt, Niu & Bogaerts, 2012).   453 
 454 
Although neither cell line significantly depleted total essential amino acid levels, the levels of total 455 
branched chain amino acids were reduced. There was evidence that a number of other amino acids 456 
being utilised by both cell lines including lysine which is important for protein synthesis which is reliant 457 
on lysine modifications such as methylation, ubiquitination, sumoylation, neddylation, biotinylation 458 
(Sadoul et al., 2008).  Taurine was one of the amino acids which significantly altered. In STC-1 cell-459 
cultured media it almost doubled in concentration, however, in pGIP/Neo cell-cultured media it 460 
approximately halved. The reasons for this differences in taurine levels are not immediately clear.   461 
5. Conclusion  462 
In conclusion these studies provide detailed profiling and characterisation of the novel pGIP/Neo cell 463 
line. Our data show for the first time that production and secretion of proglucagon peptides (GLP-1 464 
and GLP-2) are significantly decreased in pGIP/Neo compared to the progenitor STC-1 cell line. 465 
Furthermore, we have provided substantial confirmatory evidence that GIP production is increased in 466 
pGIP/Neo cells with a significantly greater percentage of pGIP/Neo cells having high GIP 467 
immunoreactivity.  However, the most surprising observation was that observed peptide levels were 468 
not reflected in the mRNA transcript levels. Despite observing greater GIP production in the pGIP/Neo 469 
  
cell line, the progenitor STC-1 cells had many more GIP mRNA transcripts.  The same discrepancy was 470 
found for GLP-1 production and proglucagon transcripts than the sub-clone pGIP/Neo cells.  Firstly 471 
this exposes the pitfall of interpreting increased transcript levels as leading to increases in incretin 472 
peptides but most interestingly it provides the first evidence suggesting that enteroendocrine 473 
hormones may be produced on translationally regulated genes. Metabolomic profiling highlighted 474 
that in many respects the utilisation and release of many nutrients (including glucose) from STC-1 and 475 
pGIP/Neo cells do not differ. However, pGIP/Neo cells utilise proportionately more 476 
proprionylcarnitine from culture media suggesting altered energy metabolism. Furthermore, 477 
pGIP/Neo cells produce more proline, serine, alanine and glycine which is indicative of overflow 478 
metabolism.   The pGIP/Neo cell line is a useful tool for investigating GIP secretion and studying 479 
changes in the co-localisation of enteroendocrine hormones. Future investigations should further 480 
probe the specific processing involved in the production of incretin hormone proteins, as such work 481 
could provide targets for diabetes pharmacotherapy.   482 
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Figure 1. Typical micrographs from the Arrayscan system. (A)  HCA images of GLP-1 (green), GIP 587 
(purple), PYY (red) and CCK (red) immunostaining in the two cell lines. GLP-1 immunoreactivity was 588 
significantly greater in the STC-1 cell line whereas GIP immunoreactivity was greatest in the 589 
pGIP/Neo cell line. PYY and CCK immunoreactivity overall did not significantly differ between cell 590 
lines. (B) Merged images of GLP-1 (green) and GIP (purple) in the cell lines.  Note the intensity of the 591 
GLP-1 (green) in the STC-1 cell line co-stain image compared with the pGIP/Neo cell line.  The 592 
pGIP/Neo cell line had greater intensity of GIP (purple).   593 
 594 
 595 
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Figure 2.  Comparative levels of GLP-1 and GLP-2 in STC-1 and pGIP/neo cell lines. The media 601 
accumulation (over 72h) and cellular content from cells were measured for (A) Total GLP-1 (active (7-602 
36) and inactive (9-36)) and (B) Total GLP-2 measured by ELISA (mean ±SEM, n=3).  Statistical 603 
differences were determined by unpaired two-tailed t-test; *P≤0.05, **P≤0.01 and ***P≤0.001.   604 
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Figure 3.  Morphometric differences between STC-1 and pGIP/Neo cell lines. High Content Analysis detected modest but significant differences in the (A) 609 
nuclei size, (B) nuclei shape, and (C) Hoechst (nuclear) staining intensity of STC-1 and pGIP/Neo cell lines (mean ± SEM n=36 wells).  Statistical differences 610 
were determined by unpaired two-tailed t-test; *P≤0.05, **P≤0.01 and ***P≤0.001.   611 
  
Figure 4. 612 
 613 
Figure 4. Comparison of intestinal hormone immunoreactivity in cell lines. High Content Analysis 614 
detected significant differences between STC-1 and pGIP/Neo cell lines in their hormone-specific 615 
immunoreactivity for (A) GLP-1 and (B) GIP (mean ± SEM; n=9). No such differences were detected for 616 
(C) PYY and (D) CCK.  Statistical differences were determined by unpaired two-tailed t-test; 617 
***P≤0.001.   618 
 619 
 620 
 621 
 622 
 623 
 624 
S
TC
-1
 
pG
IP
/N
eo
0
200
400
600
800
G
L
P
-1
 a
v
e
ra
g
e
 f
lu
o
re
s
c
e
n
c
e
 in
te
n
s
ity
***
Cell line
S
TC
-1
 
pG
IP
/N
eo
0
200
400
600
***
         Cell line
G
IP
 A
v
e
ra
g
e
 f
lu
o
re
s
c
e
n
c
e
 in
te
n
s
ity
S
TC
-1
 
pG
IP
/N
eo
0
50
100
150
ns
Cell line
P
Y
Y
 a
v
e
ra
g
e
 f
lu
o
re
s
c
e
n
c
e
 in
te
n
s
ity
S
TC
-1
 
pG
IP
0
20
40
60
80
100 ns
Cell line
C
C
K
 a
v
e
ra
g
e
 f
lu
o
re
s
c
e
n
c
e
 in
te
n
s
ity
A B
C D
  
Figure 5. 625 
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 626 
Figure 5. Gene transcript differences between STC-1 and pGIP/Neo cell lines. Graphs show mRNA 627 
copy number for (A) the proglucagon gene, (B) the glucose-dependent insulinotropic polypeptide 628 
gene (GIP), (C) the Polypeptide YY gene (PYY), (D) the cholecystokinin gene (CCK), (E) the Ubiquitin-629 
conjugating enzyme (E2D2) gene and (F) the Prohormone Convertase 3 gene (PC3) gene. mRNA copy 630 
number were determined by qRT-PCR, referenced to the 18s gene and expressed as per µg of total 631 
RNA (median, min to max, n=9). Statistical differences were determined by unpaired two-tailed t-test; 632 
**P≤0.01; ***P≤0.001.    633 
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 658 
Figure 6. Differences in the proportion of cells of particular hormone immunoreactivities. Following 659 
HCA with hormone-specific antibodies classifications were assigned to every individual cell using 660 
Boolean commands. Technical constraints meant that PYY and CCK comparisons had to be considered 661 
separately ‘undefined (Incl. CCK)/ (Incl. PYY)’.  Measurements were taken from an average total of 12 662 
350 cells across 6 wells (mean ± SEM, n=6).  (A & B) Comparisons of cells with GLP-1, GIP and PYY 663 
immunoreactivity.  (C & D) Comparisons of cells with GLP-1, GIP and CCK immunoreactivity. Statistical 664 
differences were determined by unpaired two-tailed t-tests; *P≤0.05; **P≤0.01.  Pie charts provide an 665 
overview of the abundance of each cell immunoreactivity profile (B & D).  A classification of 666 
‘undefined’ indicates intensity values below the set threshold or cells that had no immunoreactivity 667 
for the hormones tested.     668 
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Figure 7.  The increased GIP immunoreactivity of pGIP/Neo cells is due to an expansion in the 672 
number of highly immunoreactive cells. In-depth analysis of GIP immunoreactivity of all cells in 673 
individual wells from the STC-1 and pGIP/Neo cell lines (mean ± SEM, n=6 wells).  Levels were set in 674 
order to define immunoreactivity classification.  (A) Average fluorescence intensity was determined 675 
and cells with GIP immunoreactivity above the lowest quartile but below the highest quartile were 676 
classified as having ‘GIP within range’ immunoreactivity.  Cells with immunoreactivity in the highest 677 
or lowest quartiles were classified as having ‘high immunoreactivity’ or ‘low immunoreactivity’, 678 
respectively. (B) The percentage of ‘Low GIP immunoreactivity’ cells with zero GIP immunoreactivity.  679 
(C) The overall percentage of cells with GIP immunoreactivity in the STC-1 compared with the 680 
pGIP/Neo cell lines.  Statistical differences were determined by unpaired two-tailed t-tests; **P≤0.01; 681 
***P≤0.001.    682 
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Supplementary Table 1.  703 
 704 
Supplementary Table 1.  Nutrient utilisation of STC-1 and pGIP/Neo cells. Culture media from STC-1 705 
or pGIP/Neo cells underwent metabolite profiling by LC-MS both before and after a 72h culture period 706 
(mean ± SEM; n=3-6 wells of the same passage number).  Negative percentage values indicate 707 
decreased metabolite levels after incubation (i.e. nutrient utilisation). Positive percentage values were 708 
also observed indicating increased metabolite levels after incubation (i.e. metabolite production). 709 
Statistical differences were determined by unpaired two-tailed t-tests; *P≤0.05, **P≤0.01 and 710 
***P≤0.001.   711 
